v3.10.0.1

Consolidated Balance Sheets - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Current Assets
Cash	$ 109,426	$ 32,275
Prepaid expenses		1,248
Total Current Assets	109,426	33,523
TOTAL ASSETS	109,426	33,523
Current Liabilities
Accounts payable and accrued expenses	606,751	377,893
Accrued technology access fee	171,105	140,142
Convertible debentures	947,160	322,256
Convertible debentures related party	257,614
Notes payable related party		47,154
Total Current Liabilities	1,982,630	887,445
TOTAL LIABILITIES	1,982,630	887,445
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock value	51,857	26,805
Stock subscriptions	1,060,000	1,060,000
Additional paid-in capital	1,134,763	167,324
Accumulated deficit	(4,119,824)	(2,108,051)
Total Stockholders' Equity (Deficit)	(1,873,204)	(853,922)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 109,426	$ 33,523

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

Cantabio Pharmaceuticals Inc. 10-K